23andMe Holding Co. Class A Common Stock (ME) News
Filter ME News Items
ME News Results
|Loading, please wait...|
ME News Highlights
- ME's 30 day story count now stands at 9.
- Over the past 27 days, the trend for ME's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LI, DNA and GSK are the most mentioned tickers in articles about ME.
Latest ME News From Around the Web
Below are the latest news stories about 23ANDME HOLDING CO that investors may wish to consider to help them evaluate ME as an investment opportunity.
23andMe Q4 2023 Earnings Preview
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.
Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities.
Here's Why We're Not Too Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said they had personally taken a direct-to-consumer genetic health test SUNNYVALE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine.
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on Thursday, May 25, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress. The webcast
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe+ members can now gain insights on the chronic autoimmune conditionSOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the skin, joints, heart, lungs, kidneys, circulating blood cells, or brain. The report, which is powered by data from c
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategySOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheadin
Why the human genome could be health care’s holy grail
23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once ...
23andMe CEO: We see more opportunities in DNA partnerships
23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.